Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial (GlobeNewswire) - Apr 30, 2024 - "Sutro Biopharma, Inc...announced that the randomized portion (Part 2) of REFRαME-O1, the registration-directed trial of luveltamab tazevibulin (luvelta) in platinum-resistant ovarian cancer (PROC), is now open for enrollment, and the planned 50 patients in Part 1 of the trial have been enrolled....The trial includes a planned interim analysis to support a potential application for accelerated approval."
Enrollment open • Gynecologic Cancers • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor
|